In vitro antimikrobna osjetljivost Ureaplasma urealyticum

Autor: Dobrinka Petković, Sabina Cviljević, Borislav Vuković, Ankica Musil
Jazyk: chorvatština
Rok vydání: 2017
Předmět:
Zdroj: Medica Jadertina
Volume 47
Issue 3-4
ISSN: 1848-817X
0351-0093
Popis: Uvod. Ureaplazma urealyticum komenzal je donjeg urogenitalnoga trakta, te uzročnik spolno prenosivih bolesti. Antimikrobna rezistencija na tetracikline i makrolide je niska, a na kinolone visoka. Cilj. Određivanje i usporedba prevalencije i in vitro antimikrobne osjetljivosti U.urealyticum nađenih u urogenitalnim uzorcima žena reproduktivne dobi u razdoblju od lipnja 2005. do lipnja 2006. godine i u 2015. godini. Materijali i metode. U razdoblju od lipnja 2005. do lipnja 2006. godine evaluirana je in vitro antimikrobna osjetljivosti U. urealyticum urogenitalnih uzoraka 72 bolesnice s uretralnim sindromom, te su rezultati uspoređeni s podacima 181 izolata U. urealyticum dobivenih iz urogenitalnog trakta bolesnica s ginekološkom problematikom iz 2015. godine. Za identifikaciju U.urealyticum korišten je Mycoplasma IST 2 kit. In vitro antimikrobna osjetljivost izolata visoke koncentracije ≥ 104 CCU/ml određivana je metodom dilucije u bujonu na 7 antibiotika: doksiciklin, tetraciklin, azitromicin, eritromicin, klaritromicin, ciprofloksacin, ofloksacin. Rezultati. U razdoblju 2005./2006. godine prevalencija U. urealyticum u urogenitalnim uzorcima žena reproduktivne dobi iznosila je 28%, a 2015. 22,7%, (p = 0,516). Rezultati in vitro antimikrobne osjetljivosti U. urealyticum za 2005/2006. godinu i 2015. godinu bili su sljedeći: osjetljivost na doksiciklin 100% i 98,7%, na tetraciklin 100% i 98,7 %, na klaritromicin 93,7% i 89,5%, na eritromicin 90,3% i 85,6%, na azitromicin 87% i 81,2%, na ofloksacin 62% i 59,7%, na ciprofloksacin 40,3% i 28,9%. Bilježi se mala stopa rezistencije na doksiciklin i tetracikin (2,2%) i na makrolide (klaritromicin 6,3% i 10,5%; eritromicin 9,7% i 14,4%; azitromicin 13% i 18,8%), te viša na kinolone (ofloksacin 38% i 40,3%; ciprofloksacin 59% i 71,1%), a razlike u rezistencijama nisu bile statistički značajne. Zaključak. U našoj studiji nije registrirana statistički značajna razlika u prevalenciji U. urealyticum u žena reproduktivne dobi u promatranom vremenskom razdoblju u razmaku od deset godina. Rezultati in vitro antimikrobne osjetljivosti U. urealyticum pokazivali su trend porasta rezistencija, ali razlike u rezistencijama nisu bile statistički značajne. Unatoč visokoj osjetljivosti U. urealyticum na tetracikline i makrolide kao prvoj liniji terapije s obzirom na trend porasta rezistencije potrebno je kontinuirano praćenje antimikrobne osjetljivosti in vitro na lokalnoj razini radi adekvatnog izbora antimikrobika.
Introduction. Ureaplasma urealyticum is the commensal of the lower genitourinary tract and causes sexually transmitted diseases. Antimicrobial resistance to tetracyclines and macrolides is low, and to quinolones high. Objective. To determine and compare the prevalence and in vitro antimicrobial susceptibility of U. urealyticum in urogenital samples of women of reproductive age in the period from June 2005 to June 2006 and in 2015. Materials and methods. In the period from June 2005 to June 2006 in vitro antimicrobial susceptibility of U. urealyticum from urogenital samples of 72 female patients with urethral syndrome were evaluated and the results were compared with 181 isolates of U. Urealyticum from the genitourinary tract of patients with gynaecological issues in year 2015. The U. urealyticum. Mycoplasma IST 2 kit was used for identification. Invitro antimicrobial susceptibility of the isolates high concentrations ≥ 104 CCU / ml was determined by the dilution method in broth to 7 antibiotics: doxycycline, tetracycline, azithromycin, erythromycin, clarythromycin, ciprofloxacin, ofloxacin. Results. In 2005/2006, the prevalence of U. urealyticum in women of reproductive age was 28% and 22.7% in 2015 (p = 0.516). The results in vitro antimicrobial susceptibility in the period from June 2005 to June 2006 and in 2015 were the following: sensitivity to doxycycline 100% and 97.8%, tetracycline 100% and 97.8%, clarithromycin 93.7% and 89.5%, erythromycin 90.3% and 85.6%, azithromycin 87% and 81.2%, ofloxacin 62 and 59.7%, ciprofloxacin 40.3% and 28.9%. Low rate of resistance to doxycycline and tetracyclines (2.2%) and the macrolides (clarithromycin 6.3% and 10.5%; erythromycin 9.7% and 14.4%; azithromycin 13% and 18.8%) and high to quinolones (ofloxacin 38% and 40.3%; ciprofloxacin 59% and 71.1%) was registered, and there were not statistically significant differences in resistance. Conclusion. In our study, statistically significant differences in the prevalence of U. urealyticum in women of reproductive age in were not registered in the observed period. The results in vitro antimicrobial susceptibility of U. urealyticum show a trend of increasing resistance but there were no statistically significant differences. Despite the high sensitivity of U. urealyticum to tetracyclines and macrolides as a first-line treatment, due to the trend of increasing resistance, it is necessary to continuously monitor in vitro antimicrobial susceptibility in the local region for the purpose of an adequate choice of antibiotics.
Databáze: OpenAIRE
Externí odkaz: